ST. LOUIS – The U.S. Food and Drug Administration (FDA) authorized a new tool called Sepsis ImmunoScore™, created by Prenosis, Inc. This tool uses artificial intelligence (AI) to detect sepsis, a serious and hard-to-diagnose response to infection. Mercy was one of 10 study sites nationwide that helped test this tool, making the authorization possible.
Sepsis is a severe reaction to an infection and can be deadly. According to the Centers for Disease Control and Prevention, 1.7 million adults in the U.S. get sepsis each year, and one in three patients who die in hospitals had sepsis during their stay.
“We know how dangerous sepsis can be, and having tools to detect it quickly is crucial,” said Dr. Ashok Palagiri, vice president of Mercy Virtual inpatient services. “This clinical trial and research is essential in spotting sepsis early. We are grateful to have contributed to this research and we’re hopeful this tool will save lives.”
Since 2019, Mercy Research has provided 30,000 blood samples, which would have typically been destroyed and discarded, to Prenosis for this study. Prenosis used these samples to test how well the Sepsis ImmunoScore™ works. The tool combines lab and clinical data to analyze the patient's response to infection.
The Sepsis ImmunoScore™ looks at 22 different factors to give a risk score and category. This score would then be available in the hospital's electronic records, making it easily accessible to clinicians. The tool also shows how each factor affects the final score, helping the patient care team to trust and understand the results.
To read the full Prenosis, Inc., release, click here.
